LONDON WALLET
  • Home
  • Investing
  • Business Finance
  • Markets
  • Industries
  • Opinion
  • UK
  • Real Estate
  • Crypto
No Result
View All Result
LONDON WALLET
  • Home
  • Investing
  • Business Finance
  • Markets
  • Industries
  • Opinion
  • UK
  • Real Estate
  • Crypto
No Result
View All Result
LondonWallet
No Result
View All Result

Wolfe downgrades this well-known data company on concerns over macro outlook

Chaim Potok by Chaim Potok
May 26, 2023
in Investing
Wolfe downgrades this well-known data company on concerns over macro outlook
74
SHARES
1.2k
VIEWS
Share on FacebookShare on Twitter


Although data company Snowflake has strong product offerings, ongoing overhangs leave Wolfe Research with less conviction in the company’s future. “When we launched coverage in April 2022. … we were upbeat on SNOW having the best management team in software, best product, and best growth rate (potential ~50% revenue growth in CY24). While we still see all the above as possible, the current valuation does not leave much room for error, all while the macro has worsened, the competitive landscape has changed, and the growth outlook is very different,” analyst Alex Zukin wrote in a note on Thursday. Zukin downgraded Snowflake shares to peer perform from outperform. He also removed his price target, which was previously at $160. The stock closed at $147.91 after Thursday’s trading session. The analyst said macro overhangs have reduced the company’s growth expectation from 47% product revenue growth in the 2024 fiscal year, to 34% year-over-year growth. “We also see growing competition from Databricks & Microsoft who are clearly competing for the same workloads, mindshare and dollars, possibly creating incremental execution headwinds,” Zukin added. He noted that the growth of large language models and generative AI applications have caused a shift in the enterprise data storage and data infrastructure industry. To be sure, he is still optimistic about the company’s management — calling it “the best management team in software” — as well as a best software-as-a-service product. Snowflake shares ticked down 0.6% Friday before the bell. Shares are up just 3% in 2023, lagging behind the S & P 500’s gains. Meanwhile, the stock has jumped more than 16% over the last 12 months. “We further look for better visibility of near and long term growth at the current valuation,” Zukin said. —CNBC’s Michael Bloom contributed to this report.



Source link

You might also like

These are the support levels in QQQ ETF to look for as volatility picks up, according to the charts

Social Security COLA for 2026: Agency confirms when to expect announcement

Howard Marks celebrates 35 years of writing his acclaimed memos. He wasn’t sure anyone read them at first

Share30Tweet19
Previous Post

Big Lots stock tumbles toward 32-year low after losses nearly double expectations, dividend suspended

Next Post

Cummins spin-off Atmus Filtration IPO prices at $19.50 a share

Chaim Potok

Chaim Potok

Recommended For You

These are the support levels in QQQ ETF to look for as volatility picks up, according to the charts
Investing

These are the support levels in QQQ ETF to look for as volatility picks up, according to the charts

October 14, 2025
Social Security COLA for 2026: Agency confirms when to expect announcement
Investing

Social Security COLA for 2026: Agency confirms when to expect announcement

October 14, 2025
Howard Marks celebrates 35 years of writing his acclaimed memos. He wasn’t sure anyone read them at first
Investing

Howard Marks celebrates 35 years of writing his acclaimed memos. He wasn’t sure anyone read them at first

October 14, 2025
Home Depot has been in a steep downturn since mid-September. How to use options to bet on a bounce
Investing

Home Depot has been in a steep downturn since mid-September. How to use options to bet on a bounce

October 14, 2025
Next Post
Cummins spin-off Atmus Filtration IPO prices at .50 a share

Cummins spin-off Atmus Filtration IPO prices at $19.50 a share

Related News

Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short 

Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short 

February 12, 2025
South Korea’s sweeping crypto bill passes first regulatory hurdles

South Korea’s sweeping crypto bill passes first regulatory hurdles

April 26, 2023
‘Absurd’ DwP payments policy discriminates against private landlords – LandlordZONE

‘Absurd’ DwP payments policy discriminates against private landlords – LandlordZONE

June 30, 2023

Browse by Category

  • Business Finance
  • Crypto
  • Industries
  • Investing
  • Markets
  • Opinion
  • Real Estate
  • UK

London Wallet

Read latest news about finance, business and investing

  • Contact
  • Privacy Policy
  • Terms & Conditions

© 2025 London Wallet - All Rights Reserved!

No Result
View All Result
  • Checkout
  • Contact
  • Home
  • Login/Register
  • My account
  • Privacy Policy
  • Terms and Conditions

© 2025 London Wallet - All Rights Reserved!

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?